UNICHEM LABORATORIES LTD. - 506690 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Newspaper publication of the results for the quarter and year ended March 31, 201929-05-2019
29-05-2019
UNICHEM LABORATORIES LTD. - 506690 - Fixes Book Closure for Dividend & AGM
Unichem Laboratories Ltd has informed BSE that the Register of Members & Share Transfer Books of the Company will remain closed from July 22, 2019 to July 27, 2019 (both days inclusive) for the purpose of Payment of Dividend & 56th Annual General Meeting (AGM) of the Company to be held on July 27, 2019.The Dividend, if declared at the 55th AGM, shall be paid to the shareholders on August 02, 2019.25-05-2019
Unichem Laboratories Ltd - 506690 - Board recommends Dividend (AGM on July 27, 2019)
Unichem Laboratories Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 24, 2019, inter alia, has recommended Dividend of Rs. 4/- (200%) per equity share of Rs. 2/- each, for the year ended March 31, 2019, subject to approval of Shareholders at the ensuing Annual General Meeting.24-05-2019
Unichem Laboratories Ltd - 506690 - Unaudited Results For The Quarter Ended 31.3.2019 And Audited Results For The Year Ended March Ended 31.3.2019.
Unaudited results for the quarter ended 31.3.2019 and audited results for the year ended March ended 31.3.2019.24-05-2019
Unichem Laboratories Ltd - 506690 - Update on board meeting
The Board Meeting to be held on 24/05/2019 has been revised to 24/05/2019 Update on Board meeting13-05-2019
Unichem Labs allergic rhinitis drug gets tentative approval from USFDA
Unichem Laboratories Tuesday said it has received tentative approval from the US health regulator for its generic copy of allergic rhinitis Johnson & Johnson Consumer Inc's Zyrtec-D 12 Hour used for treating allergic rhinitis. The tentative nod by the US Food and Drug Administration (USFDA) is for the company's Cetirizine Hydrochloride and Pseudoephedrine Hydrochloride extended-release tablets, 5 mg/120 mg, Unichem Laboratories said in a regulatory filing. The over the counter product is also indicated as a nasal decongestant. The product will be commercialised from Unichem's Goa plant on receipt of final approval, it added.07-05-2019
Unichem Laboratories Ltd - 506690 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Unichem received tentative ANDA approval from USFDA for Unichem'sCetirizine Hydrochloride and Pseudoephedrine Hydrochloride Extended-Release Tablets USP, 5 mg/120 mg (OTC)07-05-2019
UNICHEM LABORATORIES LTD. - 506690 - Annual Secretarial Compliance Report For The Year Ended March 31, 2019
Annual Secretarial Compliance report for the year ended March 31, 201906-05-2019
Unichem Laboratories Ltd - 506690 - Board Meeting Intimation for To Consider Audited Results For Quarter And Year Ended March 31, 2019 And Recommendation Of Dividend If Any.
UNICHEM LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2019 ,inter alia, to consider and approve To consider Audited results for quarter and year ended March 31, 2019 and recommendation of dividend if any03-05-2019